Drug intelligence / Profile preview

RP-CV-1004a

Development stage: Unknown
Lead developer: Reven Holdings
Administration: Intravenous

Overview

**RP-CV-1004a** is a Reven Pharmaceuticals cardiovascular drug-development candidate listed in the company’s historical pipeline for **peripheral arterial disease** at **Phase 1**. Publicly available pipeline information does not disclose its molecular composition, therapeutic modality, biological target, route of administration, dosage form, or specific mechanism of action. It should not be assumed to be synonymous with Reven’s separately identified RJX or Rejuveinix program.

Beyond the preview

Go deeper on RP-CV-1004a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RP-CV-1004a.

Explore the full profile